Table 1.

Characteristics of the SCC cell lines

Cell lineGenderPrimary tumor locationTumor-node-metastasis*Specimen siteType of lesionGradeArea under the curve (Gy), x ± SDGefitinib IC50 (μmol/L), x ± SDCetuximab IC50 (nmol/L), x ± SD
UT-SCC-8MaleSupraglottic larynxT2N0M0LarynxPrimary11.9 ± 0.10.30±0.021.0 ± 0.3
UT-SCC-9MaleGlottic larynxT2N1M0NeckMetastasis11.4 ± 0.10.93 ± 0.251.3 ± 0.2
UT-SCC-11MaleGlottic larynxT1N0M0LarynxRecurrence22.0 ± 0.20.64 ± 0.152.7 ± 0.7
UT-SCC-19aMaleGlottic larynxT4N0M0LarynxPrimary21.7 ± 0.10.18 ± 0.026.8 ± 1.5
UT-SCC-24a1MaleTongueT2N0M0TonguePrimary22.6 ± 0.30.60 ± 0.102.1 ± 0.2
UT-SCC-24a2MaleTongueT2N0M0TonguePrimary22.6 ± 0.30.15 ± 0.031.2 ± 0.5
UT-SCC-29MaleGlottic larynxT2N0M0LarynxPrimary11.8 ± 0.20.82 ± 0.336.7 ± 2.3
UT-SCC-34MaleSupraglottic larynxT4N0M0Supraglottic larynxPrimary12.1 ± 0.10.32 ± 0.126.2 ± 1.2
UT-SCC-38MaleGlottic larynxT2N0M0LarynxPrimary22.3 ± 0.38.40 ± 1.108.2 ± 1.6
UT-SCC-40MaleTongueT3N0M0TonguePrimary12.3 ± 0.20.40 ± 0.030.6 ± 0.2
  • NOTE: Grade 1, well differentiated; grade 2, moderately differentiated; grade 3, poorly differentiated. Intrinsic radiosensitivity is expressed as the area under the survival curve equivalent to the mean inactivation dose.

  • * Tumor-node-metastasis classification according to the International Union against Cancer (1997).